Erin Finot, MS, MBA’s Post

Emmes provides full-service clinical trial support for Cell and Gene Therapy, guiding you through each phase of development. With over 40 years of experience, we offer tailored solutions that help you navigate the complexities of clinical research, from regulatory support to data management. Read our fact sheet to see how Emmes can help you advance the future of medicine together.                                                                                       #CRO #ClinicalDevelopment #CellAndGeneTherapy #ClinicalTrials #Emmes

It can take 10+ years to develop a safe and effective #cellandgenetherapy for patients, a process often complicated by the challenges associated with progressing innovative R&D processes to standardized and robust manufacturing methods. Thermo Fisher Scientific has responded to this industry challenge by developing our Rapid Development Framework™, which can streamline the complexity of #regenerativemedicine and #immunotherapy workflows for cell and gene therapies. Our upcoming webinar in partnership with #PharmaIgnite will take a deep dive into this framework, exploring how it can expedite #drugdevelopment and manufacturing timelines while staying adaptable to the unique needs of each product. Register here: http://spr.ly/6044g0Qj4

#Fast Track Designation for #ATA-100, an AAV-based gene therapy for the treatment of LGMD-R9 LGMD-R9 in #Phase 1/2 clinical trials in the US and EU. The first low-dose cohort of the study in EU shows promising initial functional results and two patients have already been treated in the high-dose cohort. Initial results show promise, with no unexpected safety issues. Updated results of the clinical trials are expected in Oct 2024.

Advancing cell and gene therapies (CGTs) globally presents unique hurdles at every step, and Labcorp has the experience and capabilities to help you overcome them. In a recent presentation for the Korea Biomedicine Industry Association (KoBIA), Maryland Rosenfeld Franklin, PhD, vice president and enterprise head of CGT at Labcorp, discussed some of these challenges and explored their solutions. Watch the recorded webinar to learn more. #CellandGeneTherapy #CellTherapy #GeneTherapy

Advancing cell and gene therapies (CGTs) globally presents unique hurdles at every step, and Labcorp has the experience and capabilities to help you overcome them. In a recent presentation for the Korea Biomedicine Industry Association (KoBIA), Maryland Rosenfeld Franklin, PhD, vice president and enterprise head of CGT at Labcorp, discussed some of these challenges and explored their solutions. Watch the recorded webinar to learn more. #CellandGeneTherapy #CellTherapy #GeneTherapy

Advancing cell and gene therapies (CGTs) globally presents unique hurdles at every step, and Labcorp has the experience and capabilities to help you overcome them. In a recent presentation for the Korea Biomedicine Industry Association (KoBIA), Maryland Rosenfeld Franklin, PhD, vice president and enterprise head of CGT at Labcorp, discussed some of these challenges and explored their solutions. Watch the recorded webinar to learn more. #CellandGeneTherapy #CellTherapy #GeneTherapy

Heading to #ATW24 this year? Let’s discuss how we can partner to simplify your cell and gene therapy research and manufacturing processes by providing the consistency, scalability, and automation you need to streamline your path to commercialization. #advancedtherapiesweek

Missed our latest webinar on the current state of cell and gene therapies? No problem! With IQVIA Biotech on-demand you can discover how efficient operational models and expert cross-functional CAGT teams are reducing the complexity of clinical trials, while accelerating their progress! Watch now to hear from our experts. https://bit.ly/40bemDo #CAGT #clinicaltrials

Advancing cell and gene therapies (CGTs) globally presents unique hurdles at every step, and Labcorp has the experience and capabilities to help you overcome them. In a recent presentation for the Korea Biomedicine Industry Association (KoBIA), Maryland Rosenfeld Franklin, PhD, vice president and enterprise head of CGT at Labcorp, discussed some of these challenges and explored their solutions. Watch the recorded webinar to learn more. #CellandGeneTherapy #CellTherapy #GeneTherapy

Advancing cell and gene therapies (CGTs) globally presents unique hurdles at every step, and Labcorp has the experience and capabilities to help you overcome them. In a recent presentation for the Korea Biomedicine Industry Association (KoBIA), Maryland Rosenfeld Franklin, PhD, vice president and enterprise head of CGT at Labcorp, discussed some of these challenges and explored their solutions. Watch the recorded webinar to learn more. #CellandGeneTherapy #CellTherapy #GeneTherapy